Tenax Therapeutics Inc (TENX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.94+8.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TENX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -57.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TENX — officer change
Dated 2026-06-29
Amendments to employment agreements providing severance and other benefits.
Why it matters: The presentation will share important details about how well TNX-103 works for patients with PH-HFpEF.
Watch forThe presentation on August 29, 2026, shows big improvements in NT-proBNP and walking distance.
Also watch forThe presentation shows no real improvements in the main or secondary goals.
Why it matters: Updates on cash runway are critical for funding operations. A shortfall could impact growth plans.
Worry ifManagement says they have enough cash to run operations until mid-2028.
Less concerning ifThe cash runway is lower. This may mean funding problems.
Why it matters: Funding is crucial for Tenax to continue its operations and projects.
Worry ifThe company announces new funding or partnerships. This helps keep operations running.
Less concerning ifThere are no updates on funding. Delays in funds raise concerns about operations.
Why it matters: Cash position affects Tenax's ability to fund operations and trials. A strong cash position supports growth.
Supportive ifCash and cash equivalents were over $118 million after Q2 earnings.
Worry ifCash and cash equivalents were under $100 million after Q2 earnings.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$293 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $698 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,247 loss on $10,000 · 92.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Earnings results will show the company's financial health. They will also show progress.
Watch forEarnings results show a big rise in revenue. They also show better cost management.
Also watch forEarnings results reveal continued losses or poor revenue growth.
Why it matters: This data will show how the product is performing. It is key for future growth.
Supportive ifThe company shares good data. It shows strong effectiveness and safety.
Worry ifThe data shows disappointing results or is not shared as planned.
Why it matters: This agreement could help with product supply and development.
Supportive ifThe company shares news of progress or success related to the agreement.
Worry ifThe agreement has delays or problems that slow product development.
Why it matters: This data is crucial for Tenax's future. Positive results could boost confidence in TNX-103.
Supportive ifThe LEVEL trial shows good results in the main goal.
Worry ifData fails to meet the primary endpoint or is delayed beyond August.
Why it matters: A big drop in NT-proBNP may show that TNX-103 could help change the disease.
Supportive ifNT-proBNP levels decrease by more than 49% in the subgroup with higher disease burden.
Worry ifNT-proBNP levels do not show real improvement in the patient group we are targeting.
Why it matters: The presentation might change how investors feel about TNX-103.
Supportive ifThe LEVEL trial results got a good response at the Late-Breaking Clinical Science session.
Worry ifThere was negative feedback about the trial results at the conference.
Why it matters: The meeting will explain the rules for TNX-103. Results will affect timelines and plans.
Supportive ifFDA provides guidance on trial design that supports a path to approval for TNX-103.
Worry ifFDA raises concerns about trial design or data that could delay approval.
Why it matters: Enrollment progress shows Tenax is serious about TNX-103. It shows the company can follow through.
Supportive ifEnrollment numbers rise a lot, showing strong interest in the LEVEL-2 trial.
Worry ifEnrollment stays the same or drops, showing possible issues with the trial or interest.
Why it matters: Topline results will show if TNX-103 can help patients with PH-HFpEF. This is crucial for future approvals.
Watch forThe main data shows a big increase in 6-minute walk distance. This is better than placebo.
Also watch forThe main data shows no big increase in 6-minute walk distance. This is like placebo.